Table 1.
Baseline characteristics of patients grouped by median TyG index.
| Variables | TyG index | P value | ||
|---|---|---|---|---|
| Overall, N = 186 | Low, N = 93 | High, N = 93 | ||
| Sex | 0.377 | |||
| Female | 84 (45.2%) | 45 (48.4%) | 39 (41.9%) | |
| Male | 102 (54.8%) | 48 (51.6%) | 54 (58.1%) | |
| Age (years) | 0.141 | |||
| ≤60 | 100 (53.8%) | 55 (59.1%) | 45 (48.4%) | |
| >60 | 86 (46.2%) | 38 (40.9%) | 48 (51.6%) | |
| BMI | 22.8 (21.1, 24.4) | 22.8 (20.7, 23.2) | 22.9 (21.5, 25.3) | 0.015 |
| NEUT (*109/L) | 3.86 (3.07, 4.97) | 3.69 (2.87, 4.75) | 3.88 (3.15, 4.99) | 0.236 |
| LYM (*109/L) | 1.20 (0.84, 1.69) | 1.13 (0.79, 1.54) | 1.27 (0.99, 1.79) | 0.078 |
| HB (g/L) | 124 (109, 137) | 121 (102, 136) | 126 (112, 140) | 0.080 |
| PLT (*109/L) | 210 (168, 279) | 210 (170, 290) | 209 (167, 263) | 0.482 |
| ALB (g/L) | 39.3 (38.3, 42.2) | 39.3 (38.2, 40.9) | 39.7 (38.5, 42.7) | 0.056 |
| FBG (mmol/L) | 5.45 (4.79, 6.69) | 5.15 (4.65, 5.61) | 6.36 (5.24, 7.98) | <0.001 |
| TG (mmol/L) | 1.34 (0.96, 1.88) | 1.00 (0.80, 1.22) | 1.87 (1.48, 2.44) | <0.001 |
| TC (mmol/L) | 4.18 (3.58, 4.73) | 4.13 (3.55, 4.61) | 4.22 (3.66, 5.01) | 0.126 |
| HDL (mmol/L) | 1.01 (0.82, 1.29) | 1.05 (0.82, 1.36) | 0.99 (0.82, 1.19) | 0.069 |
| LDL (mmol/L) | 2.46 (2.07, 2.91) | 2.45 (2.13, 2.88) | 2.46 (2.04, 2.91) | 0.880 |
| ApoA (g/L) | 1.09 (0.85, 1.40) | 1.03 (0.78, 1.37) | 1.14 (0.91, 1.40) | 0.167 |
| ApoB (g/L) | 0.85 (0.70, 0.95) | 0.82 (0.67, 0.91) | 0.85 (0.76, 0.98) | 0.009 |
| LDH | 0.761 | |||
| Low | 118 (63.4%) | 60 (64.5%) | 58 (62.4%) | |
| High | 68 (36.6%) | 33 (35.5%) | 35 (37.6%) | |
| ECOG PS | 0.203 | |||
| Low | 169 (90.9%) | 87 (93.5%) | 82 (88.2%) | |
| High | 17 (9.1%) | 6 (6.5%) | 11 (11.8%) | |
| B symptoms | 0.084 | |||
| No | 153 (82.3%) | 81 (87.1%) | 72 (77.4%) | |
| Yes | 33 (17.7%) | 12 (12.9%) | 21 (22.6%) | |
| Hans | 0.091 | |||
| Non-GCB | 121 (65.1%) | 66 (71.0%) | 55 (59.1%) | |
| GCB | 65 (34.9%) | 27 (29.0%) | 38 (40.9%) | |
| Extranodal site | 0.426 | |||
| 0 | 129 (69.4%) | 67 (72.0%) | 62 (66.7%) | |
| 1 | 57 (30.6%) | 26 (28.0%) | 31 (33.3%) | |
| Ann Arbor stage | 0.657 | |||
| Low | 81 (43.5%) | 42 (45.2%) | 39 (41.9%) | |
| High | 105 (56.5%) | 51 (54.8%) | 54 (58.1%) | |
| IPI | 0.875 | |||
| 0-2 | 127 (68.3%) | 64 (68.8%) | 63 (67.7%) | |
| 3-5 | 59 (31.7%) | 29 (31.2%) | 30 (32.3%) | |
| Ki 67 | 0.73 (0.70, 0.80) | 0.73 (0.70, 0.80) | 0.80 (0.70, 0.80) | 0.633 |
| NLR | 3.1 (2.0, 5.0) | 3.1 (2.0, 5.0) | 3.3 (2.0, 4.8) | 0.862 |
| PLR | 182 (117, 280) | 192 (117, 317) | 175 (116, 247) | 0.062 |
| SII | 654 (384, 1,280) | 687 (360, 1,360) | 645 (392, 1,164) | 0.754 |
BMI, body mass index; NEUT, neutrophil count; LYM, lymphocyte count; HB, hemoglobin; PLT, platelet count; ALB, albumin; ECOG PS, eastern cooperative oncology group performance status; GCB, germinal center B-cell; IPI, international prognostic index; LDH, lactate dehydrogenase; FBG, fasting blood glucose; TG, triacylglycerol; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA, apolipoprotein A; ApoB, apolipoprotein B; TyG index, triglyceride glucose index; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; SII, systemic immune inflammation index.